PCORI To Discuss Studies That Could Affect Medicaid Restrictions On Hep C Rx

By John Wilkerson / October 16, 2014 at 2:56 PM
The ACA's Patient-Centered Outcomes Research Institute will meet Friday to gather public input on whether comparative effectiveness research could inform hepatitis C treatment. Some of the research questions that PCORI will likely be asked to fund target reimbursement restrictions that states have put in place on Gilead Science's hepatitis C drugs, and a PCORI official says the institute does not intend to compare breakthrough hepatitis C drugs to older, less effective treatments. Stakeholders have been urging the institute to fund...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.